Peptides Similar to CagriSema

Peptides Related to CagriSema#

CagriSema occupies a unique position as the first combination product pairing amylin and GLP-1 receptor agonists in a single weekly injection. Its 20.4% mean weight loss in REDEFINE 1 places it among the most effective anti-obesity therapies, alongside tirzepatide and approaching retatrutide. The following comparisons highlight the key differences in mechanism, efficacy, and practical considerations.

Semaglutide (Wegovy)#

Semaglutide is the most direct comparator because it is literally one of the two components of CagriSema. REDEFINE 1 directly compared CagriSema to semaglutide alone in the same trial.

Within-trial comparison (REDEFINE 1, 68 weeks):

• CagriSema: -20.4% weight loss
• Semaglutide 2.4 mg alone: -14.9% weight loss
• Incremental benefit of adding cagrilintide: approximately 5.5 percentage points

This demonstrates that the amylin pathway provides clinically meaningful additional weight loss beyond GLP-1 receptor agonism alone.

Tirzepatide (Zepbound)#

Tirzepatide and CagriSema represent two different approaches to dual-mechanism anti-obesity therapy:

Cross-trial comparisons suggest very similar weight loss efficacy, though different mechanisms may produce different metabolic profiles.

Amycretin (NNC0487-0111)#

Amycretin is a single-molecule dual amylin/GLP-1 receptor agonist being developed by Novo Nordisk. It targets the same two pathways as CagriSema but in a single peptide rather than a two-peptide combination.

In Phase 2, amycretin achieved approximately 22% weight loss, suggesting potentially competitive or superior efficacy to CagriSema. However, amycretin is earlier in development (Phase 2 moving to Phase 3), while CagriSema has completed Phase 3 and filed for approval.

Retatrutide (LY3437943)#

Retatrutide's triple agonist mechanism (GIP + GLP-1 + glucagon) has produced the highest reported weight loss in clinical trials (~24.2% in Phase 2). The glucagon receptor component provides additional hepatic benefits (fat oxidation, thermogenesis) that the amylin pathway does not directly replicate.

Summary Comparison#

Comparison Context#

CagriSema belongs to the Metabolic category of research peptides. Comparing CagriSema with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to CagriSema in mechanism, indication, or therapeutic category:

CagriSema vs Semaglutide#

Similarity: Very High - Semaglutide is one of the two components of CagriSema and serves as the direct benchmark comparator

Key Differences: CagriSema adds cagrilintide (amylin agonist) to semaglutide, activating an additional appetite-regulatory pathway. This produces 20.4% vs 14.9% weight loss in the same trial (REDEFINE 1).

Advantages of Semaglutide: 5.5 percentage point greater weight loss than semaglutide alone, dual mechanism of action, 60% achieving 20%+ weight loss

Disadvantages of Semaglutide: Higher GI adverse event rate, more complex combination product, not yet approved (vs approved semaglutide), no CV outcomes data

Researchers choosing between CagriSema and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.

CagriSema vs Tirzepatide#

Similarity: High - Both achieve approximately 20% weight loss through dual-mechanism approaches, though targeting different receptor combinations

Key Differences: Tirzepatide is a single dual GIP/GLP-1 agonist molecule; CagriSema is a two-peptide combination targeting amylin + GLP-1. Different receptor targets and fundamentally different molecular approaches.

Advantages of Tirzepatide: Active comparator arms in REDEFINE 1 directly demonstrated benefit over semaglutide alone; dual amylin/GLP-1 may offer different metabolic benefits

Disadvantages of Tirzepatide: More complex (two-peptide combination), not yet approved (tirzepatide is approved), higher GI adverse events, no CV outcomes data

Researchers choosing between CagriSema and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.

CagriSema vs Amycretin#

Similarity: Very High - Both target the same two pathways (amylin + GLP-1) but amycretin is a single dual-agonist molecule while CagriSema is a two-peptide combination

Key Differences: Amycretin combines amylin and GLP-1 activity in one molecule. CagriSema uses two separate peptides (cagrilintide + semaglutide) co-formulated. Amycretin has shown up to 22% weight loss in Phase 2.

Advantages of Amycretin: More established components (semaglutide is well-characterized), larger Phase 3 data set, NDA filed

Disadvantages of Amycretin: Two-peptide combination vs single molecule, potentially more complex manufacturing, may have higher GI adverse event rate

Researchers choosing between CagriSema and Amycretin should consider the development stage, available evidence, and specific research objectives when making their selection.

CagriSema vs Retatrutide#

Similarity: Moderate - Both are next-generation multi-target obesity therapies under development

Key Differences: Retatrutide targets GIP/GLP-1/glucagon receptors (triple agonist). CagriSema targets amylin + GLP-1. Different third pathway (glucagon vs amylin) and different molecular approaches.

Advantages of Retatrutide: Larger Phase 3 data, NDA filed, dual amylin pathway for appetite regulation

Disadvantages of Retatrutide: Lower peak weight loss in cross-trial comparison (~20.4% vs ~24.2%), no glucagon receptor activity for hepatic benefits

Researchers choosing between CagriSema and Retatrutide should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• CagriSema overview and research guide
• CagriSema research evidence
• CagriSema dosing protocols